CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy

Abstract

ObjectiveTo evaluate the different kinetic parameters of serum CA125 during neoadjuvant chemotherapy (NAC) to predict optimal interval debulking surgery (IDS). MethodsThe present retrospective multicenter study included patients with advanced ovarian cancer treated with neoadjuvant platinum-based chemotherapy followed by IDS between 2002 and 2009. Demographic data, CA125 levels, radiographic data, chemotherapy and surgical-pathologic information were obtained. Univariate and multivariate analyses were performed to evaluate variables associated with complete IDS. ROC analysis was used to determine potential cut-off values to predict the likelihood of complete cytoreduction via IDS. ResultsOne hundred and forty-eight patients met the study criteria. Ninety-three patients (62.8%) had optimal cytoreduction with no residual macroscopic disease (CC-0) after IDS. In multivariate analyses, the CA125 level after the 3rd NAC was an independent predictor for optimal cytoreduction (odds ratio: 0.98 [0.97–0.99], p=0.04). The area under the ROC curve was 0.73. A threshold of 75UI/ml displayed the most predictive power. The odds ratio to predict complete cytoreduction was 3.29 [1.56–7.10] (p=0.0008). ConclusionOur data indicate that for advanced ovarian cancer, a CA125 level less than 75UI/ml after the 3rd NAC was an independent predictor factor for complete IDS.